| Title |
Safety and efficacy of peramivir for influenza treatment
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2014
|
| DOI | 10.2147/dddt.s46654 |
| Pubmed ID | |
| Authors |
Atsuko Hata, Ryoko Akashi-Ueda, Kazufumi Takamatsu, Takuro Matsumura |
| Abstract |
This report presents a review of the efficacy and safety of peramivir, a neuraminidase inhibitor that was granted Emergency Use Authorization by the US Food and Drug Administration (FDA) from October 23, 2009 to June 23, 2010 during the 2009 H1N1 pandemic. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 56 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 16% |
| Other | 7 | 12% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 5 | 9% |
| Other | 15 | 26% |
| Unknown | 11 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Agricultural and Biological Sciences | 4 | 7% |
| Immunology and Microbiology | 4 | 7% |
| Other | 8 | 14% |
| Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2014.
All research outputs
#20,653,708
of 25,371,288 outputs
Outputs from Drug Design, Development and Therapy
#1,437
of 2,268 outputs
Outputs of similar age
#194,491
of 265,618 outputs
Outputs of similar age from Drug Design, Development and Therapy
#36
of 49 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,618 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.